Press releases

Advanced Search
  • Feb 2, 2017
    -- As reported, revenues of $2.922 billion decreased 2.1 percent, which reflects the divestiture of the Respiratory Solutions business.

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.922 billion for the first fiscal quarter ended December 31,...

  • Feb 2, 2017
    Click on the links below to view results for 2017 First Fiscal Quarter:

    View Document Online PDF File of BD 2017 First Fiscal Quarter Results About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by...

  • Jan 26, 2017
    BD Launches New Initiative to Drive Simpler, Safer and Cost-Effective Medication Management

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of its new BD Institute for Medication Management Excellence, developed to...

  • Jan 23, 2017
    Indication for Congestive Heart Failure on Display at the 2017 Society of Thoracic Surgeons (STS) Meeting

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its PleurX(TM) catheter system received U.S. Food and Drug Administration (FDA) 510(k)...

  • Jan 23, 2017

    Franklin Lakes, NJ (January 23, 2017) - The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 73 cents per common share, payable on March...